- Home
- IEX vs GH Comparison
IEX vs GH Comparison
Compare IEX & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IEX | GH |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 17.3B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IEX | GH |
|---|---|---|
| Price | $226.41 | $150.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 19 |
| Target Price | ★ $229.63 | $119.79 |
| AVG Volume (30 Days) | 618.0K | ★ 2.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $3,457,500,000.00 | $982,021,000.00 |
| Revenue This Year | $4.09 | $33.30 |
| Revenue Next Year | $4.36 | $28.27 |
| P/E Ratio | $141.63 | ★ N/A |
| Revenue Growth | 5.77 | ★ 32.88 |
| 52 Week Low | $157.25 | $40.36 |
| 52 Week High | $230.18 | $145.84 |
Technical Indicators
Market Signals| Indicator | IEX | GH |
|---|---|---|
| Relative Strength Index (RSI) | 62.02 | 76.75 |
| Support Level | $204.03 | $123.88 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 5.33 | 6.53 |
| MACD | 0.42 | 0.61 |
| Stochastic Oscillator | 76.49 | 96.08 |
Price Performance
Historical ComparisonAbout IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. The company generated $3.5 billion in revenue in 2025.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.